Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18272305rdf:typepubmed:Citationlld:pubmed
pubmed-article:18272305lifeskim:mentionsumls-concept:C0027651lld:lifeskim
pubmed-article:18272305lifeskim:mentionsumls-concept:C0006675lld:lifeskim
pubmed-article:18272305lifeskim:mentionsumls-concept:C0025932lld:lifeskim
pubmed-article:18272305lifeskim:mentionsumls-concept:C1416433lld:lifeskim
pubmed-article:18272305lifeskim:mentionsumls-concept:C0033992lld:lifeskim
pubmed-article:18272305lifeskim:mentionsumls-concept:C0079189lld:lifeskim
pubmed-article:18272305lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:18272305lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:18272305lifeskim:mentionsumls-concept:C0870883lld:lifeskim
pubmed-article:18272305lifeskim:mentionsumls-concept:C0392747lld:lifeskim
pubmed-article:18272305lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:18272305pubmed:issue1-2lld:pubmed
pubmed-article:18272305pubmed:dateCreated2008-4-8lld:pubmed
pubmed-article:18272305pubmed:abstractTextIn vivo studies of the effectiveness of various forms of calcium pterin reveal significant antitumor activity associated with (1:4, mol/mol) calcium pterin (CaPterin), (1:2, mol/mol) calcium pterin, dipterinyl calcium pentahydrate (DCP), as well as unexpectedly for a calcium chloride dihydrate solution in nude mice with MDA-MB-231 xenographs. Stepwise regression analysis of nine plasma cytokine and indoleamine 2,3-dioxygenase (IDO) metabolite levels identified four effects correlated to (1:4, mol/mol) calcium pterin administration: (1) decreased IL-6, (2) increased IL-10, (3) decreased IFN-gamma, and (4) increased kynurenine. CONCLUSION: (1:4, mol/mol) CaPterin exerts significant (by Spearman rank order correlation) dose-response antitumor activity in nude mice with MDA-MB-231 xenographs, and sustains both inflammatory and anti-inflammatory changes in the levels of certain plasma factors.lld:pubmed
pubmed-article:18272305pubmed:languageenglld:pubmed
pubmed-article:18272305pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18272305pubmed:citationSubsetIMlld:pubmed
pubmed-article:18272305pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18272305pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18272305pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18272305pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18272305pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18272305pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18272305pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18272305pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18272305pubmed:statusMEDLINElld:pubmed
pubmed-article:18272305pubmed:monthMaylld:pubmed
pubmed-article:18272305pubmed:issn0378-5173lld:pubmed
pubmed-article:18272305pubmed:authorpubmed-author:RheingoldArno...lld:pubmed
pubmed-article:18272305pubmed:authorpubmed-author:FuchsDietmarDlld:pubmed
pubmed-article:18272305pubmed:authorpubmed-author:PfleidererWol...lld:pubmed
pubmed-article:18272305pubmed:authorpubmed-author:DiPasqualeAnt...lld:pubmed
pubmed-article:18272305pubmed:authorpubmed-author:MohenoPhillip...lld:pubmed
pubmed-article:18272305pubmed:issnTypePrintlld:pubmed
pubmed-article:18272305pubmed:day1lld:pubmed
pubmed-article:18272305pubmed:volume355lld:pubmed
pubmed-article:18272305pubmed:ownerNLMlld:pubmed
pubmed-article:18272305pubmed:authorsCompleteYlld:pubmed
pubmed-article:18272305pubmed:pagination238-48lld:pubmed
pubmed-article:18272305pubmed:meshHeadingpubmed-meshheading:18272305...lld:pubmed
pubmed-article:18272305pubmed:meshHeadingpubmed-meshheading:18272305...lld:pubmed
pubmed-article:18272305pubmed:meshHeadingpubmed-meshheading:18272305...lld:pubmed
pubmed-article:18272305pubmed:meshHeadingpubmed-meshheading:18272305...lld:pubmed
pubmed-article:18272305pubmed:meshHeadingpubmed-meshheading:18272305...lld:pubmed
pubmed-article:18272305pubmed:meshHeadingpubmed-meshheading:18272305...lld:pubmed
pubmed-article:18272305pubmed:meshHeadingpubmed-meshheading:18272305...lld:pubmed
pubmed-article:18272305pubmed:meshHeadingpubmed-meshheading:18272305...lld:pubmed
pubmed-article:18272305pubmed:meshHeadingpubmed-meshheading:18272305...lld:pubmed
pubmed-article:18272305pubmed:meshHeadingpubmed-meshheading:18272305...lld:pubmed
pubmed-article:18272305pubmed:meshHeadingpubmed-meshheading:18272305...lld:pubmed
pubmed-article:18272305pubmed:meshHeadingpubmed-meshheading:18272305...lld:pubmed
pubmed-article:18272305pubmed:meshHeadingpubmed-meshheading:18272305...lld:pubmed
pubmed-article:18272305pubmed:meshHeadingpubmed-meshheading:18272305...lld:pubmed
pubmed-article:18272305pubmed:meshHeadingpubmed-meshheading:18272305...lld:pubmed
pubmed-article:18272305pubmed:meshHeadingpubmed-meshheading:18272305...lld:pubmed
pubmed-article:18272305pubmed:meshHeadingpubmed-meshheading:18272305...lld:pubmed
pubmed-article:18272305pubmed:meshHeadingpubmed-meshheading:18272305...lld:pubmed
pubmed-article:18272305pubmed:meshHeadingpubmed-meshheading:18272305...lld:pubmed
pubmed-article:18272305pubmed:year2008lld:pubmed
pubmed-article:18272305pubmed:articleTitleCytokine and IDO metabolite changes effected by calcium pterin during inhibition of MDA-MB-231 xenograph tumors in nude mice.lld:pubmed
pubmed-article:18272305pubmed:affiliationSanRx Pharmaceuticals, Inc., 603 Colima Street, La Jolla, CA 92037, USA. phil.moheno@sanrx.comlld:pubmed
pubmed-article:18272305pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18272305lld:pubmed